These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26500340)

  • 1. Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity.
    Yu X; Menard M; Prechl J; Bhakta V; Sheffield WP; Lazarus AH
    Blood; 2016 Jan; 127(1):132-8. PubMed ID: 26500340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FcγRIII in ITP: it ain't over 'til it's over.
    McCrae KR
    Blood; 2016 Jan; 127(1):11-2. PubMed ID: 26744437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP.
    Gil Gonzalez L; Won KD; Tawhidi Z; Cummins E; Cruz-Leal Y; Tundidor Cabado Y; Sachs UJ; Norris PAA; Shan Y; Bhakta V; Li J; Samudio I; Silva-Moreno B; Cerna-Portillo L; Pavon Oro A; Bergqvist P; Chan P; Moorehead A; Sholzberg M; Sheffield WP; Lazarus AH
    Blood Adv; 2024 Apr; 8(8):1869-1879. PubMed ID: 38330193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-inflammatory activity of CD44 antibodies in murine immune thrombocytopenia is mediated by Fcγ receptor inhibition.
    Norris PAA; Kaur G; Khan R; Zhu G; Ni H; Lazarus AH
    Blood; 2021 Apr; 137(15):2114-2124. PubMed ID: 33662988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors.
    Ortiz DF; Lansing JC; Rutitzky L; Kurtagic E; Prod'homme T; Choudhury A; Washburn N; Bhatnagar N; Beneduce C; Holte K; Prenovitz R; Child M; Killough J; Tyler S; Brown J; Nguyen S; Schwab I; Hains M; Meccariello R; Markowitz L; Wang J; Zouaoui R; Simpson A; Schultes B; Capila I; Ling L; Nimmerjahn F; Manning AM; Bosques CJ
    Sci Transl Med; 2016 Nov; 8(365):365ra158. PubMed ID: 27856797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting FcγRs to treat antibody-dependent autoimmunity.
    Yu X; Lazarus AH
    Autoimmun Rev; 2016 Jun; 15(6):510-2. PubMed ID: 26854400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects.
    Yu X; Menard M; Seabright G; Crispin M; Lazarus AH
    Transfusion; 2015 Jun; 55(6 Pt 2):1501-11. PubMed ID: 25752470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions.
    Qureshi OS; Rowley TF; Junker F; Peters SJ; Crilly S; Compson J; Eddleston A; Björkelund H; Greenslade K; Parkinson M; Davies NL; Griffin R; Pither TL; Cain K; Christodoulou L; Staelens L; Ward E; Tibbitts J; Kiessling A; Smith B; Brennan FR; Malmqvist M; Fallah-Arani F; Humphreys DP
    Sci Rep; 2017 Dec; 7(1):17049. PubMed ID: 29213127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
    Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
    Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.
    Spirig R; Campbell IK; Koernig S; Chen CG; Lewis BJB; Butcher R; Muir I; Taylor S; Chia J; Leong D; Simmonds J; Scotney P; Schmidt P; Fabri L; Hofmann A; Jordi M; Spycher MO; Cattepoel S; Brasseit J; Panousis C; Rowe T; Branch DR; Baz Morelli A; Käsermann F; Zuercher AW
    J Immunol; 2018 Apr; 200(8):2542-2553. PubMed ID: 29531170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
    Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
    Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent Requirement of Fc-Fcγ Receptor Interactions for
    Wang S; Ren H; Jiang W; Chen H; Hu H; Chen Z; Zhou P
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of Fcgamma receptors in murine autoimmune thrombocytopenia.
    Biburger M; Aschermann S; Lux A; Nimmerjahn F
    Ann Hematol; 2010 Jul; 89 Suppl 1():25-30. PubMed ID: 20179927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes.
    Bailey EM; Choudhury A; Vuppula H; Ortiz DF; Schaeck J; Manning AM; Bosques CJ; Hoppe AD
    Front Immunol; 2020; 11():617767. PubMed ID: 33679705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages.
    Nagelkerke SQ; Dekkers G; Kustiawan I; van de Bovenkamp FS; Geissler J; Plomp R; Wuhrer M; Vidarsson G; Rispens T; van den Berg TK; Kuijpers TW
    Blood; 2014 Dec; 124(25):3709-18. PubMed ID: 25352126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Dual Targeting of FcRn and FcγRs
    Monnet C; Jacque E; de Romeuf C; Fontayne A; Abache T; Fournier N; Dupont G; Derache D; Engrand A; Bauduin A; Terrier A; Seifert A; Beghin C; Longue A; Masiello N; Danino L; Nogre M; Raia A; Dhainaut F; Fauconnier L; Togbe D; Reitinger C; Nimmerjahn F; Stevens W; Chtourou S; Mondon P
    Front Immunol; 2021; 12():728322. PubMed ID: 34512662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse immune thrombocytopenia is associated with Th1 bias and expression of activating Fcγ receptors.
    Nishimoto T; Okazaki Y; Numajiri M; Kuwana M
    Int J Hematol; 2017 May; 105(5):598-605. PubMed ID: 28028748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg.
    Song S; Crow AR; Siragam V; Freedman J; Lazarus AH
    Blood; 2005 Feb; 105(4):1546-8. PubMed ID: 15479722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors.
    Loyau J; Malinge P; Daubeuf B; Shang L; Elson G; Kosco-Vilbois M; Fischer N; Rousseau F
    MAbs; 2014; 6(6):1621-30. PubMed ID: 25484053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.